Understanding how Epstein Barr virus causes lymphomas after organ transplants
Official title: Epstein Barr Virus Driven Mechanisms of Post Transplant Lymphoproliferative Disease
Funded at Stanford University · NIH-10913587 · Data updated 2026-11-12
This study is looking at how the Epstein Barr virus can cause certain types of cancer in people who have had organ transplants, and it aims to find out how specific parts of the virus affect the immune system, which could help improve prevention and treatment for those patients.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $596,508 |
| NIH project number | 5U01CA275305-02 |
| Project ID | NIH-10913587 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have received solid organ transplants and are at risk for developing EBV-related lymphomas.
✕Less likely to help
Patients who have not undergone solid organ transplantation or those without EBV infection may not benefit from this research.
What this research studies
This research investigates the mechanisms by which the Epstein Barr virus (EBV) leads to serious B cell lymphomas in individuals who have received solid organ transplants. The study focuses on understanding how specific viral genes, particularly the latent membrane protein 1 (LMP1), contribute to the development of post-transplant lymphoproliferative disease (PTLD). By analyzing samples from transplant recipients, the researchers aim to uncover the alterations in immune responses that predispose some patients to develop EBV-related lymphomas. This work could provide insights into better prevention and treatment strategies for affected patients.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for preventing and treating lymphomas caused by Epstein Barr virus in transplant recipients.
How similar studies have gone: Previous studies have shown promising results in understanding the role of EBV in lymphomagenesis, indicating that this research builds on established findings.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Martinez, Olivia M — Stanford University
- Study coordinator: Martinez, Olivia M
Related research
Other NIH-funded projects on the same topics.
-
Targeting early oral GVHD to improve mouth health after stem cell transplant
A study at UW–Madison will explore why some transplant patients develop painful oral GVHD and test ideas to prevent and lessen mouth-related problems.
-
Innate and Adaptive Immunoregulation in Liver Transplant Ischemia/Reperfusion Injury
A liver transplant-focused project investigates how the body’s early and later immune responses affect transplant failure or success after reperfusion.
-
Exercise-based frailty program for people awaiting lung transplants
A tailored exercise and lifestyle program is being tested to reduce frailty and improve outcomes for people waiting for a lung transplant.
-
Diabetes and Donor Tissue in Corneal Transplants
This grant studies whether corneas from donors with diabetes affect the success of Descemet membrane endothelial keratoplasty (DMEK) and what factors predict better or worse outcomes.
-
Microbial clues to diagnose and predict infections in kidney transplant patients
A patient-focused project will look for microbial biomarkers in stool, blood, and urine to help doctors predict and diagnose infections in people who have had a kidney transplant.
-
Medicare Advantage and Transplant Access for Rural and Vulnerable Communities
Aimed at understanding how Medicare Advantage affects early steps to kidney transplant for adults in rural or socioeconomically challenged groups.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.